BRANFORD, Conn. / Jul 30, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston August 13-15, 2024.
Jeff Hawkins, Quantum-Si's Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13th, at 11:00 AM ET.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
| Last Trade: | US$2.34 |
| Daily Change: | 0.05 2.18 |
| Daily Volume: | 10,149,156 |
| Market Cap: | US$427.190M |
September 23, 2025 September 08, 2025 August 05, 2025 June 17, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
